Use of blockbuster anti-obesity drugs like Wegovy and Zepbound is growing, with about 1 in 8 adults in the U.S. saying they currently take the medications.
Federal regulators are telling drugmakers to remove label warnings about potential suicidal thoughts and behaviors from their blockbuster weight-loss drugs.
“People, I think, have started looking outside the box when it comes to health care. And they’re turning more to wellness and functional medicine, more holistic ways of looking at their health than just going to the doctor, picking up prescriptions.”
A groundbreaking study from Cleveland Clinic reveals that bariatric surgery offers significant long-term health benefits over GLP-1 medications for weight loss.
Recent research from Cleveland Clinic reveals that variations in the Neurobeachin gene may significantly influence weight loss success with GLP-1 medications.
Some of the more than a dozen states that cover the high cost of GLP-1 drugs like Wegovy, Ozempic and Zepbound through Medicaid or state employee insurance programs are scrambling to lessen the budgetary squeeze from fast-rising costs.
While West Virginia's employee health insurance program covers drugs like Ozempic for people with type 2 diabetes, officials decided to indefinitely pause covering their use for weight loss patients because of the cost.
Use of diabetes and obesity medications such as Ozempic, Wegovy and other so-called GLP-1 drugs has soared among teens and young adults.
